The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Vanda Pharmaceuticals

  • VNDA
  • Consumer Products
  • Latest 12.40
  • Currency US$
  • Change 0.01
  • Percent Change 0.081 %
  • Volume 172,646
  • Thu Sep 18, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 12.47
  • Previous Close 12.39
  • High 12.585
  • Low 12.25
  • Bidx6 11.77
  • Askx10 13.25
  • 52-week High03/24 19.25
  • 52-week Low11/08 5.70
  • Beta 2.306
  • Market Cap 415.40M
  • EPS -1.83
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield


Financials & Calendars

Income Statement

  • Sales $34,950,000
  • Earnings $-42,610,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $43,260,000
  • Current Ratio 2.32

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $120,980,000
  • Liabilities $99,990,000
  • Liabilities-to-Equity Ratio 4.77

Price Ratios

  • Price to Sales 11.89
  • Price to Book 19.81
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Aug 7 n/a Nov 6 n/a
Surprises Feb 13 27.78% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Sep 18, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Related Securities
Symbol Type Latest % Chg


  • Howard Pien Chairman of the Board and Dire
  • Mihael H. Polymeropoulos Chief Executive Officer & Pres
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office


Phone: (202)-734-3400
Fax: (202)-2961450

Ideas & Discussion

Live Discussion of VNDA on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.